Importantly, recent therapeutic strategies have focused on reversing T cell exhaustion by blocking inhibitory receptors with immune checkpoint inhibitors, thus restoring the effector functions of exhausted CD8+ T cells in the context of cancer immunotherapy. Here, CD8A is linked to cancer.